Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. - Wikidata - wikimedia - TriplyDB

Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.

Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.

http://www.wikidata.org/entity/Q37463330

about

Statistical Methods for Establishing Personalized Treatment Rules in Oncology Genomic profiling in luminal breast cancer Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?Genome-based risk prediction for early stage breast cancer.TOX3 is expressed in mammary ER(+) epithelial cells and regulates ER target genes in luminal breast cancer.Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer.Identification and prioritization of candidate genes for symptom variability in breast cancer survivors based on disease characteristics at the cellular level.HOX genes: Major actors in resistance to selective endocrine response modifiers.Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncolog Metastasis dormancy in estrogen receptor-positive breast cancer.Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.Two-gene expression ratio as predictor for breast cancer treated with tamoxifen: evidence from meta-analysis.Molecular markers for breast cancer diagnosis, prognosis and targeted therapy.Alternative Polyadenylation in Triple-Negative Breast Tumors Allows NRAS and c-JUN to Bypass PUMILIO Posttranscriptional Regulation.Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.Biomarker analysis for oncology.Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer.Clinical utility of gene-expression signatures in early stage breast cancer.Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.Extended Endocrine Therapy: Is 5 Years Enough?Does patient education work in breast cancer? Final results from the global CARIATIDE study.Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer.TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis.An unmet need: tailoring extended adjuvant endocrine therapy.Endocrine Therapy for Early Breast Cancer: Updated Review.Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer.Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG).Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.Optimal duration of adjuvant endocrine therapy: how to apply the newest data.Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women.Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.Extended Adjuvant Endocrine Therapy for Postmenopausal Women: Treating Many to Benefit a Few.Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling.Clinical application and utility of genomic assays in early-stage breast cancer: key lessons learned to date.Optimal management of luminal breast cancer: how much endocrine therapy is long enough?An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers Genomic Testing in the Management of Early-Stage Breast Cancer

P2860

Q26786366-69213359-4597-495C-AE39-94AC2A60CF18 Q26862681-F9A968BC-D6C5-4A7A-8BFC-5700E6A6C9F0 Q33684843-FC5BA7CB-1ED6-4B91-877A-DFE4ADF6F0B9 Q34359289-77F469A5-D8B2-4DD3-A419-404968F9B627 Q35074030-A5BF6FE9-12F7-4E16-A144-8F98E35A4229 Q36322870-4BEFB010-2833-46F0-9D03-766F1C596F1A Q36428743-82CA1117-387E-48CC-82C3-F63E3077FD92 Q36545353-3B4145F3-6486-4AC0-B6E1-4CBADD1845DF Q36684067-ED112E6A-E10B-4918-A5B0-190B38935E60 Q36880407-8F4D7D4B-8000-4056-A666-1E86968835AF Q37169337-0C0CE495-AC9B-4FA8-BA4A-2AF715E90FC3 Q37427008-425CAE8E-CCCE-45CE-BF71-7904BB9AAFA0 Q37570901-F706D2B8-19D2-4EB3-8A06-9F1E09B15DC7 Q38165072-B8CFC8A4-A92E-43EA-8EA6-E7142E358B4D Q38236904-827BFEEE-EC53-44BC-83F1-2EA947EC299C Q38290569-1003CE5F-2DC0-49B5-8E0B-414023F1A574 Q38547729-888FF5A5-9695-497D-B5D0-154E1369A137 Q38578640-27F1F860-9E9C-462B-B871-97A1F80BD634 Q38635960-67D623BE-B956-4BB8-874A-07C9B35E45B9 Q38754717-FAD99202-D3D9-4E8C-9823-4B2970DA6EE3 Q38883281-C6C7D40A-1FDE-4C5A-99C9-A1078516E015 Q38934318-4F099F01-D829-4284-BD6C-AABF5BE4752B Q39057658-385D3536-87FF-49C1-8D07-8D620C1B8B2E Q41242766-8DA9B2FB-0E3D-4240-AD61-E1DFA31AA9EA Q41598833-4A6D560C-DD29-419C-AFB9-C390559DA6EE Q42813847-B7DA05C0-C546-41F2-B7EF-AA839E09014F Q47161589-FCA2B775-53A2-414E-9785-F851EF56720F Q47821919-C1418B8E-5004-4F29-9146-D8456D75F305 Q48203476-A4941DFC-989E-4BCE-9D03-D7D5308E2C61 Q48234773-25142B47-303D-4198-B662-F2203961E92B Q49177338-05EE4063-4B53-4D13-BD20-414633E81EB4 Q49334420-51E2EDB5-35C8-4C79-953C-7E3DC9759B9A Q49951544-7918CB9E-E7E0-42EC-A74E-5198B427612D Q50042351-AABDD864-5A17-4421-A2DA-955EB0A6FE05 Q54198492-E96ED8F3-EB68-4E37-9517-BCF51DA65B6D Q54942720-94BB4091-89E1-4FF0-8D69-FD457D72DD12 Q55334991-630A59F2-31B2-4113-B052-6F3CCBB4A8E0 Q55424072-07378B8A-EC67-4BD9-9496-4D3D1F299D58 Q57106403-B36CE798-F04F-4AED-9325-3440BFC23F60 Q57117421-6B4121CA-D2FB-4FC6-8757-79B996CA8D6F

P2860

Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.

http://www.wikidata.org/entity/Q37463330

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 June 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Prediction of late disease rec ...... y the HOXB13/IL17BR biomarker.

@en

Prediction of late disease rec ...... y the HOXB13/IL17BR biomarker.

@nl

type

label

Prediction of late disease rec ...... y the HOXB13/IL17BR biomarker.

@en

Prediction of late disease rec ...... y the HOXB13/IL17BR biomarker.

@nl

prefLabel

Prediction of late disease rec ...... y the HOXB13/IL17BR biomarker.

@en

Prediction of late disease rec ...... y the HOXB13/IL17BR biomarker.

@nl

P1433

Q37463330-904E2C9A-ECE2-4E0F-86E6-F74E25CAC151

P1476

Q37463330-D2D45CEA-F792-4A44-A163-9FC11DD35341

P2093

Q37463330-0688B157-DCEB-4F16-BD78-6E38AC7B2D05

Q37463330-12DFE0EF-111B-4BDE-B539-04D7C033A1BA

Q37463330-153F1BA2-92E3-4AD6-AEAB-B269BD4C9DD5

Q37463330-1F24C991-684E-4199-9CEC-6D89C5B27DCB

Q37463330-20AD35B1-92AF-4319-AE47-AC522C686043

Q37463330-446501B0-F0F5-4A7D-860B-93DEA973151E

Q37463330-5915871E-3531-4BF7-962C-C792F7B9A08E

Q37463330-61B95878-D671-4CB3-907B-7F8A5615AA08

Q37463330-7CCE282D-C253-4C79-94D2-F740F7564DB8

Q37463330-8D3F7A83-A65A-4213-B4A0-8D2D21CA7D4C

P2860

Q37463330-077EB392-064F-4020-B06F-808B4B1395C6

Q37463330-0A2F46D9-C71D-4906-A606-104DD9FEDE83

Q37463330-1407AD1C-9C11-4A38-9081-4ACA41030B7E

Q37463330-299C81E7-8ACC-4BB8-8A01-1C4B0EAE72E3

Q37463330-2EC73C2A-B646-46B2-8951-BB60DB9184D4

Q37463330-2FCAFB45-1FB5-4B9C-B347-CC4ED16AD178

Q37463330-33A550F0-CCF3-4CC9-A71A-61C2D44D20E4

Q37463330-35B512F3-9AE6-43D6-884A-26B919E3DCD7

Q37463330-46818769-5F0C-409B-8892-6659D6789CA0

Q37463330-547412A2-D8A4-486B-9DD8-DEEBC7E71FE7

P304

Q37463330-044FA11E-52F3-459B-8857-65A7CE3480C0

P31

Q37463330-BD61F72C-8EFB-418F-8346-A6F6725CF465

P356

Q37463330-B7A9D397-6421-45FD-800C-502C857A8CA5

P407

Q37463330-FEA14970-E921-4547-BAA5-F0C7A0BAC428

P433

Q37463330-9877A3FA-2A6C-414C-BAF7-C1F913B67696

P478

Q37463330-571910DD-43FB-474D-9E42-AA2F2E488A9A

P577

Q37463330-54E93A8E-10A6-41C9-AD07-CF1E8DB80CA9

P5875

Q37463330-5CAD4D8A-1BC1-446C-B472-D15F1DC07EAE

P698

Q37463330-71F7D9F7-B169-4CAF-9301-7658E0B2A442

P921

Q37463330-5B0EE0CA-4686-4141-91B6-B541F11F4F63

P932

Q37463330-CCE085F9-461C-47CA-A8A7-F345E5AB95D4

P356

P1433

Journal of the National Cancer Institute

P1476

Prediction of late disease rec ...... y the HOXB13/IL17BR biomarker.

@en

P2093

Atul K Bhan

http://www.w3.org/2001/XMLSchema#string

Catherine A Schnabel

http://www.w3.org/2001/XMLSchema#string

David L Rimm

http://www.w3.org/2001/XMLSchema#string

Dennis C Sgroi

http://www.w3.org/2001/XMLSchema#string

Dianne M Finkelstein

http://www.w3.org/2001/XMLSchema#string

Dongsheng Tu

http://www.w3.org/2001/XMLSchema#string

Elizabeth Zarrella

http://www.w3.org/2001/XMLSchema#string

Erin Carney

http://www.w3.org/2001/XMLSchema#string

Hyman B Muss

http://www.w3.org/2001/XMLSchema#string

Jackie Szymonifka

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer

Clinical application of the 70-gene profile: the MINDACT trial

A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Simultaneous inference in general parametric models

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

Use of archived specimens in evaluation of prognostic and predictive biomarkers

Patient adherence to aromatase inhibitor treatment in the adjuvant setting.

P304

1036-1042

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJT146

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

243968482

http://www.w3.org/2001/XMLSchema#string

P698

23812955

http://www.w3.org/2001/XMLSchema#string

P921

P932

3888138

http://www.w3.org/2001/XMLSchema#string